Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Lapatinib with Capecitabine for HER2+ Breast Cancer with CNS Metastases
NCT02650752Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2016
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lapatinib in HER2-positive metastatic breast cancer, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Jan 2016; status: completed.
02
Drugs
lapatinib
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT02650752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02650752.